Worth reading
93Important
Scored from 1 of 5 sectionsDirection
Mixed performance
Direction inferred from the company’s description.Scale
709
¥ millionWording
Conditional
How definitive the wording is.Details of issuance or disposal
Changes to the use of proceeds and scheduled expenditure period relating to the issuance of stock acquisition rights through a third-party allotment (the Ninth and Tenth Series Stock Acquisition Rights)
Amount of funds to be raised
Actual funds raised: ¥1,760,615,708 (¥36,090,000 raised from the issuance of stock acquisition rights and ¥1,738,000,000 raised from the exercise of stock acquisition rights, less ¥13,474,292 in expenses)
Estimated issuance expenses
¥13,474,292 (expenses included in the actual funds raised)
Specific use of funds
Capital expenditure for the Chinese subsidiaryAmount ¥832 million / Scheduled timing of expenditures December 2023 to December 2025 (expenditure completed)
Investment in human resources (recruitment expenses and personnel expenses)Amount ¥198 million / Scheduled timing of expenditures December 2023 to December 2025 (expenditure completed)
M&A fundsAmount ¥21 million / Scheduled timing of expenditures December 2023 to April 2026 (expenditure completed)
Working capitalAmount ¥709 million / Scheduled timing of expenditures May 2026 to December 2027
Terms of the stock acquisition rights
Number of Stock Acquisition Rights
Of the 10,000 Tenth Series Stock Acquisition Rights, the Company acquired and cancelled 9,000. The total number issued and the number of unexercised Ninth Series Stock Acquisition Rights are Not disclosed
Reason for acquisition without consideration
The disclosure states that the Company acquired and cancelled 9,000 of the Tenth Series Stock Acquisition Rights, but the reason for the acquisition is Not disclosed
Most recent equity financing
Timing Announced on 20 November 2023 / Type Issuance of the Ninth and Tenth Series Stock Acquisition Rights through a third-party allotment / Amount Initial expected amount of funds raised: ¥2,658,900,000
Impact on Business Performance
The impact of the changes has already been incorporated into the performance forecasts for the nanomaterials business in the Medium-Term Management Plan 2026. If any material impact on business performance is identified in the future, it will be disclosed promptly.
| Item | Details |
|---|---|
| Type of issuance or disposal | Changes to the use of proceeds and scheduled expenditure period relating to the issuance of stock acquisition rights through a third-party allotment (the Ninth and Tenth Series Stock Acquisition Rights) |
| Amount of funds to be raised | Actual funds raised: ¥1,760,615,708 (¥36,090,000 raised from the issuance of stock acquisition rights and ¥1,738,000,000 raised from the exercise of stock acquisition rights, less ¥13,474,292 in expenses) |
| Estimated issuance expenses | ¥13,474,292 (expenses included in the actual funds raised) |
| Specific use of funds | Details Capital expenditure for the Chinese subsidiary / Amount ¥832 million / Scheduled timing of expenditures December 2023 to December 2025 (expenditure completed), Details Investment in human resources (recruitment expenses and personnel expenses) / Amount ¥198 million / Scheduled timing of expenditures December 2023 to December 2025 (expenditure completed), Details M&A funds / Amount ¥21 million / Scheduled timing of expenditures December 2023 to April 2026 (expenditure completed), Details Working capital / Amount ¥709 million / Scheduled timing of expenditures May 2026 to December 2027 |
| Number of Stock Acquisition Rights | Of the 10,000 Tenth Series Stock Acquisition Rights, the Company acquired and cancelled 9,000. The total number issued and the number of unexercised Ninth Series Stock Acquisition Rights are Not disclosed |
| Reason for acquisition without consideration | The disclosure states that the Company acquired and cancelled 9,000 of the Tenth Series Stock Acquisition Rights, but the reason for the acquisition is Not disclosed |
| Most recent equity financing | Timing Announced on 20 November 2023 / Type Issuance of the Ninth and Tenth Series Stock Acquisition Rights through a third-party allotment / Amount Initial expected amount of funds raised: ¥2,658,900,000 |
| Impact on Business Performance | The impact of the changes has already been incorporated into the performance forecasts for the nanomaterials business in the Medium-Term Management Plan 2026. If any material impact on business performance is identified in the future, it will be disclosed promptly. |
Items this document does not state (20)
Number of shares to be issued or disposed ofIssue price and disposal priceTotal issue valuePayment dateIntended allotteeIntended allottee's holding policyDilution RateTotal number of issued sharesBasis for determining the amount to be paidExercise priceExercise periodTransfer restriction periodConditions for lifting transfer restrictionsCategories and Number of Persons CoveredTotal Stock-Based CompensationUnderwriter / lead underwriterOverallotmentStock Split RatioProcedures under the Corporate Code of ConductMajor shareholders after the offering
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Working capital will be secured because advance procurement payments for transactions in the EU are substantial and a 4- to 6-month time lag is expected before the related sales proceeds are collected.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.